9 results about "Infected patient" patented technology

The application discloses a gel preparation preparation method for improving cervical HPV infection and establishing a preventive barrier, relates to the technical field of gel preparation, and aims to solve the technical problems that the existing treatment methods are mostly focused on treating infected patients, and there are obvious deficiencies in the prevention of HPV infection, especially in establishing an effective preventive barrier in uninfected people, including: a crushing mechanism, which is mainly used for crushing raw materials, the crushing mechanism comprises a cabinet body, a cabinet door is arranged on one side of the cabinet body, a crushing barrel is arranged in the cabinet door, and a rotating motor matched with the crushing barrel is arranged on the cabinet door; a reverse osmosis mechanism, which is mainly used for controlling the osmotic pressure of the gel. The application has the advantages of activating local immune cells of the cervix, promoting cytokine secretion, enhancing the immune clearance ability of the body to HPV virus, providing long-acting preventive protection for the cervix, and reducing the risk of HPV infection.

The invention belongs to the technical field of in-vitro molecular detection of pathogenic microorganisms, and particularly relates to a primer probe combination, a kit and a detection system for detecting entamoeba histolytica, giardia lamblia and cryptosporidium and application of the primer probe combination, the kit and the detection system. The primer and probe combination is obtained by optimizing primer and probe design and comprises primers and probes for detecting entamoeba histolytica, giardia blue and cryptosporidium, three types of parasite pathogens can be identified and detected on suspected infected patients at a time, the flux is high, the detection time is short, the detection time is short, and the detection efficiency is high. And the kit has the advantages of strong specificity, high sensitivity, good stability, short reaction time and the like. Furthermore, the kit containing the primer and probe combination is formed by optimizing a reaction system, a single tube in the kit can contain all primers, probes and components required by PCR reaction in a fully premixed form, the reaction system does not need to be prepared, the operation is simple, and the consumed time is short.

The invention relates to a pyridone derivative as shown in a formula (I) or a stereoisomer thereof, a prodrug of the pyridone derivative, a pharmaceutically acceptable salt, a pharmaceutical composition containing the formula (I), and application of the pyridone derivative or the stereoisomer thereof, the prodrug of the pyridone derivative, the pharmaceutically acceptable salt and the pharmaceutical composition in preparation of a medicine for preventing and / or treating HIV (Human Immunodeficiency Virus) infection. The compound disclosed by the invention has remarkable anti-HIV virus activity, relatively low solubility and very low clearance rate, is suitable for developing a long-acting injection prevention and treatment scheme, and is used for preparing a medicine of an HIV virus integrase inhibitor or a medicine composition containing the medicine so as to benefit patients infected by HIV viruses.

The application discloses a protein polypeptide for marker use in clinical diagnosis of non-tuberculous mycobacterial infection, comprising an amino acid sequence as shown in SEQ NO.1 or an amino acid sequence as shown in SEQ NO.2. The application also discloses proteins and uses thereof. The protein polypeptide of the application can specifically stimulate lymphocytes of a mycobacterium abscessus infected patient to secrete cytokines such as IFN-gamma, and therefore, the protein polypeptide can be used for marker use in clinical diagnosis of the mycobacterium abscessus infected patient.

This invention discloses a biomarker for evaluating the immune status of COVID-19 vaccines and its application. The biomarker includes any one or a combination of at least two of the following SARS-CoV-2 viral peptides: M1, N16, N24, S15, S39, S44, S64, S82, S95, S104, or S115. This invention accurately identifies differences in peptide-specific antibody responses between asymptomatic and symptomatic patients. Through clustering heatmaps, it determines the differences in responses to peptides such as M1, N24, S15, S64, S82, S104, and S115 between vaccinated individuals and infected individuals. This effectively distinguishes between infected patients and vaccinated individuals, as well as between asymptomatic and symptomatic patients, providing a reference for COVID-19 treatment and peptide vaccine development.

The invention discloses a joint detection marker for diagnosis and differential diagnosis of rhinomyelitis and application of the joint detection marker. The marker comprises cell factor E-selectin protein / nucleic acid in a blood sample of an infected patient and an antibody aiming at rhinomyelitis HCP1 protein. The invention creatively provides the combined marker for diagnosing the infection of the rhinotrichum-like disease, and the combined marker can be used for differential diagnosis of the current symptom and the previous infection of the rhinotrichum-like disease. The combined marker also has the potential of being used as a target spot for preventing and treating burkholderia pseudomallei infection.

The invention provides an antibody combined with HPV66 L1 protein or an antigen binding fragment thereof and a pharmaceutical composition containing the antibody, and further provides a polynucleotide molecule for coding the antibody or the antigen binding fragment thereof, and an expression vector for expressing the antibody or the antigen binding fragment thereof. The antibody or the antigen binding fragment thereof can be widely applied to infection detection of the HPV66 virus in a clinical sample, can be prepared into vaginal gel, vaginal cleaning liquid, external washing liquid, vaginal suppository, freeze-dried powder, vaginal effervescent tablets and the like, is used for prevention and / or treatment of HPV66 infected patients, and can effectively improve the clinical negative conversion rate of the HPV66 patients. The invention has important significance on female reproductive health and public health prevention and control.

Coronavirus disease of 2019 (COVID-19) is an acute viral infection that can trigger complicated immune system responses depending on the host. This disclosure discloses immunotherapy methods combining immunomodulators and antivirals to prevent and to reduce the severity of a COVID-19 infection. Successful treatment of COVID-19 requires prevention, early recognition and detection, the ruling out of co-infections, serial laboratory monitoring, and clinical monitoring for worsening and timely treatments during the acute phase and post-viral syndrome. Using this disclosure as preventive, management and therapeutic options for COVID-19, infected patients can be more resilient to viral challenges, recovering faster with less organ damages and adverse residual effects.

The invention belongs to the technical field of biological medicine, and particularly relates to application of polypeptide in distinguishing infection of novel coronavirus (SARS-CoV-2) with different severity degrees, and the polypeptide is KTFPPTEPKKDKKKK (SEQ ID NO: 1) and / or ALPQRQKKQQTVTLL (SEQ ID NO: 2). By detecting the abundance of the IgA antibody combined with the polypeptide, the severity of the SARS-CoV-2 infected patient can be effectively distinguished.